Exalenz Bioscience & #226; �(TM)s BreathID & #194; & #174; Hp & amp; BreathID Hp Lab ...

Important new testing option for an infection that impacts nearly 20 million U.S. children and may have significant negative impacts on long-term health MODI'IN, Israel and MANASQUAN, N.J., March 13, 2018 - Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the BreathID® Hp...This story is related to the following:Clinical Medical Equipment
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news